Renal failure, its complications and attendant therapies, are often associated with seizures. It has been estimated that seizures occur in 10% of patients with chronic renal failure (1).
Renal failure as a direct cause of seizures
Acute renal failure is a potent epileptogenic state, although the specific metabolic cause is unknown. Patients with progressive uremia may develop muscle fasciculations, twitching, asterixis, tremor, myoclonus, chorea or hemiballismus, involuntary movements that reflect neuronal hyperexcitability at the level of the peripheral nerves, spinal cord, basal ganglia and cerebral cortex. Generalized tonic-clonic convulsions are most common after 8 to 11 days of untreated anuria, and often appear in the context of severe myoclonic jerks. Such convulsions are repetitive.
Severe myoclonus may be repetitive and sometimes simulates ictal activity. Asterixis or termulousness, at rest or with action, can also simulate focal motor seizures. Unlike uremic seizures, myoclonus and tremors are often stimulus-sensitive, and usually move from one part of the body to another, involving the limbs or the face. An electroencephalogram is definitive in resolving any doubt, but is rarely necessary.
True focal motor or other focal seizure activity is not typical of metabolically triggered seizures, and should suggest the possibility of focal cerebral lesions such as subdural hematoma, ischemic infarction, or intracerebral hematoma. Pre-existing focal cerebral lesions, particularly in the elderly, may also serve as foci for focal motor, complex partial, adversive, or aphasic seizures.
Rapid increases in blood urea nitrogen (BUN) may be a potent stimulus for seizures, but the presence of so many co-variant metabolic abnormalities makes it difficult to assign causation to any single factor. The absolute BUN level is not a good predictor of seizures. The serum BUN to calcium ratio has been offered as a good predictor of convulsions (13) .
More specific pro-convulsant metabolites have been
The International Journal of Artificial Organs I Vol. 17 I no. 5, 1994 /pp. 247-251 investigated, particularly guanidino compounds which are elevated in the blood and brain of uremic patients (DeDeyn 1990). Methylguanidine, for example, causes seizures in cats and rabbits, as do creatine and creatinine. These compounds, as well as guanidine and guanidino succinic acid, inhibit gamma-aminobutyric acid (GABA) and glycine responses in cultured spinal cord neurons (2) . Anti-GABA compounds are potent convulsant agents, and loss of the inhibitory neurotransmitter action of GABA is thought by some to be an important factor in human epileptogenesis. Just as convulsions may represent a late manifestation in untreated acute renal failure, so they tend to occur late in the course of chronic renal failure. Moderate to severe acidosis or water intoxication are often present. Myocardial infarction or arrhythmias may be associated with seizures in moribund patients. The occurrence of seizures in patients with chronic renal failure should always prompt a search for focal cerebral lesions such as intracranial hemorrhage or infection.
Malignant hypertension
One of the problems faced by the clinician confronted with seizures in a patient with renal failure is to determine the immediate cause of seizures in the presence of multiple known (or possible) risk factors. A typical dilemma is the occurrence of seizures in the uremic patient with malignant hypertension. To make things even more difficult, cerebral infarction may complicate hypertensive encephalopathy (10 out of 34 cases in one series) (22) and serve as a focus for seizures.
Careful clinical analysis will help determine the correct diagnosis. Myoclonus and asterixis are typical of uremic and other metabolic encephalopathies, for example, but are not observed in hypertensive encephalopathy. Cortical blindness is fairly common in hypertensive encephalopathy, but would not be caused by uremia. Headache is often prominent in hypertensive encephalopathy. Focal seizures, or focal seizures ©by Wichtig Editore, 1994 0391-3988/247-05 $02.50/0 with secondary generalization, should suggest the presence of localized cerebral pathology such as infarction or hemorrhage.
The diastolic blood pressure is generally over 130-140 mm Hg in symptomatic patients. However, the rate of rise of blood pressure and the patient's usual pressure are also important. They are relevant not only to the patient's clinical tolerance of hypertension but also to the rate and level of blood pressure reduction considered safe and desirable.
Intravenous phenytoin may be used for hypertensive .seizures, but treatment of hypertension is paramount. Phenytoin may be stopped when blood pressure has normalized.
lschemic stroke and intracerebral hemorrhage
Cerebral infarction is the most common neurological complication in renal transplant patients, and may serve as a focus for acute or late seizures (3) . Concomitant risk factors such as diabetes mellitus, atherosclerosis, hypertension, polycythemia, and abnormal coagulation and rheological conditions are probably responsible for stroke, rather than renal failure itself.
lntracerebral hemorrhage may occur in the context of hypertensive encephalopathy, and is heralded by the appearance of focal neurological signs, headache, depressed levels of consciousness, or seizures.
Antibiotics
Renal failure may increase free levels of certain pro-convulsant antibiotics such as penicillin (10 to 20 times normal), causing myoclonus and eventually convulsions. Scattered myoclonus may precede the seizures, reflecting generalized cerebral irritability. Ciprofloxacin, imipenem/cilastatin and other betalactam antibiotics may also be associated with seizures in patients with renal failure or with cerebral lesions causing leakage of the blood-brain barrier (4).
Dialysis
Seizures acutely related to dialysis were fairly common soon after the introduction of hemodialysis, as part of the disequilibrium syndrome. Typically, vigorous dialysis would be followed within several hours 248 (or up to two days) by headache, irritability, nausea, and sometimes convulsions, signs of a metabolic encephalopathy. Cerebral water intoxication associated with delayed extraction of urea and other small diffusible molecules from the intracellular compartment of the brain, and consequent movement of water into neurons, are the putative mechanisms. Refinement of dialysis technique has made the full-blown "reverse urea syndrome" an unusual occurrence (5) .
Dialysis dementia
In 1972 an alarming and stereotyped syndrome, dialysis dementia, was reported in dialysis patients, and later in children with chronic renal failure who had never been dialyzed (6) . Onset is usually heralded by speech hesitancy or stammering, followed by dysphasia, gait disturbance, seizures, and progressive dementia. Both sexes and every age group are vulnerable. The mean time of onset is 3 months after starting dialysis (range 1 month to 9 years). The condition is usually fatal within six months (7) . The EEG shows a characteristic pattern of slowing and epileptiform discharges.
Epidemiological analysis suggested that relatively aluminum-rich dialysate and the use of aluminum gel phosphate binders might be risk factors. Sucralfate, in fact, the basic aluminum salt of sucrose sulfate, has been reported to precipitate symptoms of acute aluminum toxicity including seizures. High brain levels of aluminum are found in most affected patients. Remission has been reported with removal of aluminum from the diet or dialysates or after chelation with deferoxamine (8) .
Low levels of the inhibitory neurotransmitter gammaamino-butyric acid (GABA) have been reported in patients dying with dialysis dementia, and may be responsible for seizures (9, 10) . Successful treatment of the speech disorder and other symptoms with benzodiazepines, known to enhance GABA activity, has been reported (11) .
Aluminum may inhibit dehydrobiopteridine reductase, an enzyme involved in the synthesis of the catecholamines. Congenital deficiency of this enzyme is accompanied by myoclonus and severe seizures. Chelation has been recommended in those with aluminum levels over 200 mcg/I (6) . Rapid chelation has been reported to cause reversible exacerbation of symptoms in some patients (12) .
Although the pathophysiology of dialysis encephalopathy remains obscure, reduction of exposure to aluminium by altering dialysate and avoiding oral aluminum has been successful in lowering the risk of the disease.
Acute aluminum toxicity
A rare, fatal syndrome of acute confusion, myoclonus, seizures, and coma has been reported in patients with renal fialure taking oral citrate and aluminum hydroxide gel (13) . Extremely high blood levels of aluminum were found, and enhanced gastrointestinal absorption of aluminum was thought to be the etiology.
Subdura/ hematoma
Patients on chronic dialysis are at increased risk for bleeding into the subdural space, although the degree of risk has not been well quantified. Clinical signs are headache, somnolence, transient or progressive focal neurological signs such as hemiparesis, dysphasia, or seizures. A plain CT scan or MRI scan of the head is usually diagnostic.
Transplantation
Although successful renal transplantation obviates some of the seizure risks associated with uremia and dialysis, it introduces other risks of seizures. Posttransplant convulsions may occur in the context of acute graft rejection and accompanying hypertension, for example. Sudden shifts in electrolytes after successful transplantation may underlie early seizures (14) .
In one review of 154 children receiving kidney transplantation there were 31 (20%) with seizures after surgery (15) . Eight of the 31 had had preoperative seizures as well. Focal seizures, both simple partial (e.g., focal motor seizures) and complex partial (so-called psychomotor or temporal lobe) seizures were reported as well as tonic-clonic convulsions. Associated conditions were found in most and included acute renal failure (sometimes part of acute rejection) and hypertension. Pre-existing central nervous systems (CNS) injuries, and viral or fungal CNS infections were less frequently involved. Most patients had only a single seizure, even though anticonvulsants were given in only about half of the cases. Such treatment decisions should be made with circumspection: phenytoin and phenobarbital are often specifically avoided lest they interfere with the effects of corticosteroids, but other enzyme-inducing antiepileptic drugs such as carbamazepine theoretically pose the same risk. Sodium valproate is not an enzyme inducer, but has the disadvantage of being unavailable in parenteral form.
Cyclosporin toxicity
Neurological side effects of cyclosporin include tremors, ataxia, confusion, paresthesias, and weakness. Encephalopathic signs including seizures have been also reported specifically in renal transplant patients receiving cyclosporin, usually at high doses (16) . Visual disturbances such as cortical blindness or visual agnosias are characteristic (17) . Transient, focal white matter lesions, usually located posteriorly, reflect the cerebral area most affected and have been demonstrated in some patients. Hypomagnesemia may occur in other patients with cyclosporin-associated seizures, suggesting that magnesium replacement may be an appropriate preventive measure or treatment (18) .
Recombinant human erythropoietin
Seizures have been reported in a small proportion (3-5%) of patients with renal failure receiving recombinant-human erythropoietin (19) . Most of these patients had hypertensive encephalopathy. Careful adjustment of dosage and maintenance of modest hematocrit levels with phlebotomy has been shown to reduce excessive increases in blood viscosity and hypertension which are probably responsible for erhythropoieti n-associeted seizures.
Antiepi/eptic drugs ( AEDs) and renal failure
Renal failure may be accompanied by a reduction in glomerular and/or tubular functions, a rise in total body water with increased extracellular water, variable degrees of hypoalbuminemia, electrolyte irr1balance, uremia, and functional changes in the gastrointestinal tract. These changes may modify drug bioavailability, reduce plasma protein binding of acidic drugs, increase the apparent volume of distribution, lead to accumulation of polar metabolites, and effect durg clearance rates (20) . In some cases an elevation of the free fraction of a drug may lead to symptoms of toxicity even when the ordinary serum level (which reflects bound plus unbound levels) is normal. The phenytoin free fraction, for example, which is normally around 6-10%, increases in uremic patients to as high as 30%, and valproate may be similarly affected (21) . The dosage of phenorbarbital and primidone, much of which is excreted unchanged in urine, must also be individualized on the basis of the glomerular filtration rate (22) . When in doubt about possible toxicity or therapeutic failure of AEDs, measuring serum free levels allows an accurate measure of the physiologically active fraction of an AED.
Impaired kidney function has not been reported to cause modification in either bioavailability of clearance rates of carbamazepine. However, carbamazepine may exert a significant antidiuretic effect with increased risk of fluid retention.
Kidney-transplant patients with significant decreases in cyclosporin levels after the introduction of carbamazepine, phenytoin, or phenobarbital have been described (23, 24) . All of these drugs are inducers of the hepatic cytochrome P450 enzyme system. Valproic acid does not have such an effect.
Dialysis adds another potential complication. Of the commonly used AEDs, only phenobarbital, primidone, and ethosuximide are dialyzed in significant amounts, sometimes requiring post-dialysis dosage supplements. On the other hand phenytoin and valproate levels are not significantly altered by hemodialysis or peritoneal dialysis. As a general rule, however, post-dialysis seizures are usually due to the disequilibrium syndrome rather than to acute AED withdrawal.
